AR037390A1 - Formulacion farmaceutica - Google Patents
Formulacion farmaceuticaInfo
- Publication number
- AR037390A1 AR037390A1 ARP020104386A ARP020104386A AR037390A1 AR 037390 A1 AR037390 A1 AR 037390A1 AR P020104386 A ARP020104386 A AR P020104386A AR P020104386 A ARP020104386 A AR P020104386A AR 037390 A1 AR037390 A1 AR 037390A1
- Authority
- AR
- Argentina
- Prior art keywords
- alpha
- drug
- pharmaceutical
- methylpropiono
- toluidide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un producto farmacéutico para administrar a un paciente, que comprende: 4'-ciano-alfa',alfa',alfa'-trifluoro-3-(4-fluorofenilsulfonil)-2-hidroxi-2-metilpropiono-m-toluidida, o una sal o solvato de la misma aceptable para el uso farmacéutico, en una dispersión sólida con un polímero entérico que tiene un pKa de entre 3 y 6, producto que comprende además un antiestrógeno (por ejemplo, citrato de tamoxifeno) y/o un inhibidor de aromatasa (por ejemplo, anastrozol). La presente también se relaciona con una dosis farmacéutica de la droga y el anti-estrógeno/inhibidor de aromatasa provista por tal formulación. Una ventaja es en el tratamiento y/o la prevención de al menos un efecto colateral seleccionado entre ginecomastia, sensibilidad anormal en las mamas, sofocos, impotencia y reducción en la libido, al tiempo que se incrementa la biodisponibilidad de la droga; se reduce la variabilidad entre pacientes en las concentraciones en plasma de la 4'-ciano-alfa',alfa',alfa'-trifluoro-3-(4-fluorofenilsulfonil)-2-hidroxi-2-metilpropiono-m-toluidida; se mejora la estabilidad de almacenamiento de la droga; y/o se trata y/o reduce el riesgo de cáncer de próstata en un paciente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103839A SE0103839D0 (sv) | 2001-11-16 | 2001-11-16 | Pharmaceutical formulation & product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037390A1 true AR037390A1 (es) | 2004-11-10 |
Family
ID=20286023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104386A AR037390A1 (es) | 2001-11-16 | 2002-11-14 | Formulacion farmaceutica |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050038111A1 (es) |
| EP (1) | EP1448168B1 (es) |
| JP (1) | JP2005514355A (es) |
| KR (1) | KR20050044468A (es) |
| CN (1) | CN1615122A (es) |
| AR (1) | AR037390A1 (es) |
| AT (1) | ATE350016T1 (es) |
| AU (1) | AU2002343024A1 (es) |
| BR (1) | BR0214135A (es) |
| CA (1) | CA2466986A1 (es) |
| DE (1) | DE60217390T2 (es) |
| ES (1) | ES2278063T3 (es) |
| IL (1) | IL161902A0 (es) |
| MX (1) | MXPA04004591A (es) |
| NO (1) | NO20042502L (es) |
| SE (1) | SE0103839D0 (es) |
| TW (1) | TW200406200A (es) |
| UY (1) | UY27539A1 (es) |
| WO (1) | WO2003043606A1 (es) |
| ZA (1) | ZA200403689B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0302847A3 (en) * | 2001-02-27 | 2005-05-30 | Astrazeneca Ab | Pharmaceutical formulation comprising bicalutamide |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| US7332525B2 (en) * | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
| US7226622B2 (en) | 2003-09-18 | 2007-06-05 | Boston Scientific Scimed, Inc. | Chemoablation of tissue using biodegradable, solid salt dosage forms |
| CA2554025A1 (en) * | 2004-01-28 | 2005-08-11 | Androscience Corporation | Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof |
| CN101123951A (zh) * | 2004-08-31 | 2008-02-13 | 辉瑞产品公司 | 包括低溶解性药物和聚合物的药物剂型 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| CN101128195A (zh) * | 2005-02-23 | 2008-02-20 | 阿斯利康(瑞典)有限公司 | 用于递送增加的稳态血浆水平的比卡鲁胺 |
| JP2008534575A (ja) * | 2005-03-29 | 2008-08-28 | ユーエスヴィー リミテッド | ビカルタミドの調製のための新規プロセス |
| US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| US20090246781A1 (en) * | 2008-02-21 | 2009-10-01 | Robert Klem | Method for early determination of recurrence after therapy for prostate cancer |
| CA2737528A1 (en) * | 2008-09-17 | 2010-03-25 | Mylan Laboratories, Inc. | Granulates, process for preparing them and pharmaceutical products containing them |
| DK3725778T3 (da) | 2012-09-11 | 2021-09-20 | Medivation Prostate Therapeutics Llc | Formuleringer af enzalutamid |
| CN107049972A (zh) * | 2017-03-17 | 2017-08-18 | 万特制药(海南)有限公司 | 一种含有来曲唑固体分散体的分散片及其制备工艺 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3121152A1 (de) * | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie" |
| US4895715A (en) * | 1988-04-14 | 1990-01-23 | Schering Corporation | Method of treating gynecomastia |
| CA2181358A1 (en) * | 1994-01-21 | 1995-07-27 | Nancy M. Gray | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
| GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| US6139875A (en) * | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
-
2001
- 2001-11-16 SE SE0103839A patent/SE0103839D0/xx unknown
-
2002
- 2002-10-31 TW TW091132270A patent/TW200406200A/zh unknown
- 2002-11-13 UY UY27539A patent/UY27539A1/es not_active Application Discontinuation
- 2002-11-14 MX MXPA04004591A patent/MXPA04004591A/es unknown
- 2002-11-14 AT AT02779684T patent/ATE350016T1/de not_active IP Right Cessation
- 2002-11-14 US US10/495,012 patent/US20050038111A1/en not_active Abandoned
- 2002-11-14 EP EP02779684A patent/EP1448168B1/en not_active Expired - Lifetime
- 2002-11-14 ES ES02779684T patent/ES2278063T3/es not_active Expired - Lifetime
- 2002-11-14 JP JP2003545287A patent/JP2005514355A/ja not_active Withdrawn
- 2002-11-14 BR BR0214135-3A patent/BR0214135A/pt not_active Application Discontinuation
- 2002-11-14 IL IL16190202A patent/IL161902A0/xx unknown
- 2002-11-14 KR KR1020047007359A patent/KR20050044468A/ko not_active Application Discontinuation
- 2002-11-14 CA CA002466986A patent/CA2466986A1/en not_active Abandoned
- 2002-11-14 AR ARP020104386A patent/AR037390A1/es unknown
- 2002-11-14 WO PCT/GB2002/005159 patent/WO2003043606A1/en active IP Right Grant
- 2002-11-14 CN CNA028272277A patent/CN1615122A/zh active Pending
- 2002-11-14 AU AU2002343024A patent/AU2002343024A1/en not_active Abandoned
- 2002-11-14 DE DE60217390T patent/DE60217390T2/de not_active Expired - Fee Related
-
2004
- 2004-05-13 ZA ZA200403689A patent/ZA200403689B/en unknown
- 2004-06-15 NO NO20042502A patent/NO20042502L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050044468A (ko) | 2005-05-12 |
| EP1448168A1 (en) | 2004-08-25 |
| MXPA04004591A (es) | 2004-08-13 |
| UY27539A1 (es) | 2003-07-31 |
| IL161902A0 (en) | 2005-11-20 |
| ES2278063T3 (es) | 2007-08-01 |
| DE60217390T2 (de) | 2007-11-15 |
| US20050038111A1 (en) | 2005-02-17 |
| NO20042502L (no) | 2004-08-09 |
| DE60217390D1 (de) | 2007-02-15 |
| EP1448168B1 (en) | 2007-01-03 |
| JP2005514355A (ja) | 2005-05-19 |
| SE0103839D0 (sv) | 2001-11-16 |
| AU2002343024A1 (en) | 2003-06-10 |
| BR0214135A (pt) | 2004-10-13 |
| WO2003043606A1 (en) | 2003-05-30 |
| CN1615122A (zh) | 2005-05-11 |
| ZA200403689B (en) | 2006-06-28 |
| ATE350016T1 (de) | 2007-01-15 |
| CA2466986A1 (en) | 2003-05-30 |
| TW200406200A (en) | 2004-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037390A1 (es) | Formulacion farmaceutica | |
| AR032912A1 (es) | Formulacion farmaceutica | |
| AR054234A1 (es) | Composicion farmaceutica para el tratamiento del cancer | |
| MX9200992A (es) | Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion. | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| BRPI0515573A (pt) | copolìmero por blocos, preparação de micela e agente anticáncer contendo a mesma como o ingrediente ativo | |
| CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| ATE309798T1 (de) | Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate | |
| CR8352A (es) | Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos | |
| PL349335A1 (en) | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| HN2004000232A (es) | " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden." | |
| CA2376916A1 (en) | Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist | |
| DE60211139D1 (de) | Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| SE9901573D0 (sv) | New compounds | |
| AR073265A1 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
| BRPI0520797B8 (pt) | forma de dosagem farmacêutica comprimida em bicamadas | |
| BR0109747A (pt) | Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática | |
| BRPI1008000A2 (pt) | composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto. | |
| JP2015218147A (ja) | リラナフタート含有外用医薬組成物 | |
| BR0111051A (pt) | Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente | |
| AR045263A1 (es) | Metodo, kit y composicion farmaceutica para tratar infecciones virales | |
| SE0103838D0 (sv) | Pharmaceutical formulation & product | |
| SE9901572D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |